深圳欣博盛生物科技有限公司

SPRED1 Antibody / Sprouty-related EVH1 domain-containing protein 1

SPRED1 antibody detects Sprouty-related EVH1 domain-containing protein 1 (also known as Sprouty-related protein with EVH1 domain 1), a membrane-associated signaling inhibitor that modulates the Ras/MAPK pathway. Encoded by the SPRED1 gene on chromosome 15q14, this protein belongs to the SPRED family, which acts as a negative regulator of growth factor signaling by inhibiting RAF activation downstream of Ras. SPRED1 contains an N-terminal Enabled/VASP homology 1 (EVH1) domain that mediates binding to other signaling proteins, a central c-Kit binding region, and a C-terminal Sprouty-related cysteine-rich domain required for membrane localization. Through these domains, SPRED1 fine-tunes MAPK activity, ensuring controlled cellular proliferation, differentiation, and migration.

SPRED1 plays critical roles during embryonic development, particularly in neural crest cell differentiation and vascular morphogenesis. Its inhibitory effect on Ras signaling prevents excessive ERK activation, which could otherwise lead to developmental abnormalities or oncogenic transformation. Mutations in SPRED1 cause Legius syndrome, an autosomal dominant disorder characterized by caf�-au-lait macules, freckling, and learning difficulties that phenotypically overlap with neurofibromatosis type 1. This highlights the gene's importance in the neurofibromin-Ras regulatory axis, as SPRED1 interacts directly with neurofibromin (NF1) to recruit it to the plasma membrane for Ras inactivation.

The SPRED1 antibody is an important reagent for signal transduction, developmental biology, and cancer research. Western blot analysis identifies a 55 kilodalton band corresponding to SPRED1, while immunofluorescence reveals punctate cytoplasmic and membrane-associated staining. Expression of SPRED1 is widespread in brain, lung, liver, and vascular endothelium, reflecting its role in growth factor signaling regulation. Loss or downregulation of SPRED1 enhances Ras/MAPK signaling and has been associated with melanoma, hepatocellular carcinoma, and acute myeloid leukemia. Conversely, forced expression of SPRED1 suppresses ERK phosphorylation and reduces tumor cell invasiveness.

At the molecular level, SPRED1 acts as a scaffold that connects neurofibromin and Ras, stabilizing NF1-mediated GTPase activation. It also interferes with RAF recruitment to the plasma membrane, thereby preventing downstream MEK and ERK activation. These inhibitory effects are critical for maintaining normal signaling thresholds. In vascular endothelial cells, SPRED1 regulates VEGF-induced angiogenesis and vessel branching. In neurons, it contributes to axon guidance and synaptic stability by modulating localized MAPK signaling. The SPRED1 antibody is thus widely used to investigate feedback mechanisms in receptor tyrosine kinase signaling and to identify dysregulated pathways in cancer and developmental syndromes.

SPRED1 expression is tightly controlled by transcriptional and post-translational mechanisms, including phosphorylation and ubiquitination that determine its stability and subcellular localization. The protein's interaction with lipid rafts allows spatially restricted inhibition of MAPK signaling near the plasma membrane. NSJ Bioreagents provides the SPRED1 antibody validated for its applications, enabling detailed characterization of SPRED1's role in Ras pathway modulation, angiogenesis, and neurodevelopmental regulation.

Human

Rabbit

WB, ICC/IF, FACS, ELISA

Rabbit IgG

E.coli-derived human SPRED1 recombinant protein (Position: F45-K322) was used as the immunogen for the SPRED1 antibody.

Polyclonal (rabbit origin)

Immunogen affinity purified

After reconstitution, the SPRED1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Lyophilized

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml

美国